Bcr-Abl Stabilizes Beta-catenin in Chronic Myeloid Leukemia Through Its Tyrosine Phosphorylation

Overview

Journal EMBO J

Specialties Biotechnology
Molecular Biology

Date 2007 Feb 24

PMID 17318191

Citations 106

Authors

Addolorata Maria Luce Coluccia

Angelo Vacca

Mireia Dunach

Luca Mologni

Sara Redaelli

Victor H Bustos

Daniela Benati

Lorenzo A Pinna

Carlo Gambacorti-Passerini

Affiliations

Soon will be listed here.

Abstract

Self-renewal of Bcr-Abl(+) chronic myeloid leukemia (CML) cells is sustained by a nuclear activated serine/threonine-(S/T) unphosphorylated beta-catenin. Although beta-catenin can be tyrosine (Y)-phosphorylated, the occurrence and biological relevance of this covalent modification in Bcr-Abl-associated leukemogenesis is unknown. Here we show that Bcr-Abl levels control the degree of beta-catenin protein stabilization by affecting its Y/S/T-phospho content in CML cells. Bcr-Abl physically interacts with beta-catenin, and its oncogenic tyrosine kinase activity is required to phosphorylate beta-catenin at Y86 and Y654 residues. This Y-phospho beta-catenin binds to the TCF4 transcription factor, thus representing a transcriptionally active pool. Imatinib, a Bcr-Abl antagonist, impairs the beta-catenin/TCF-related transcription causing a rapid cytosolic retention of Y-unphosphorylated beta-catenin, which presents an increased binding affinity for the Axin/GSK3beta complex. Although Bcr-Abl does not affect GSK3beta autophosphorylation, it prevents, through its effect on beta-catenin Y phosphorylation, Axin/GSK3beta binding to beta-catenin and its subsequent S/T phosphorylation. Silencing of beta-catenin by small interfering RNA inhibited proliferation and clonogenicity of Bcr-Abl(+) CML cells, in synergism with Imatinib. These findings indicate the Bcr-Abl triggered Y phosphorylation of beta-catenin as a new mechanism responsible for its protein stabilization and nuclear signalling activation in CML.

Citing Articles

Actin Cytoskeleton Remodeling Accompanied by Redistribution of Adhesion Proteins Drives Migration of Cells in Different EMT States.

Ilnitskaya A, Litovka N, Rubtsova S, Zhitnyak I, Gloushankova N Cells. 2024; 13(9.

PMID: 38727316 PMC: 11083118. DOI: 10.3390/cells13090780.

A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells.

Zhang X, Wang Y, Lu J, Xiao L, Chen H, Li Q Cell Mol Biol Lett. 2023; 28(1):83.

PMID: 37864206 PMC: 10589942. DOI: 10.1186/s11658-023-00496-z.

Visinin-like 1, a novel target gene of the Wnt/β-catenin signaling pathway, is involved in apoptosis resistance in colorectal cancer.

Tage H, Yamaguchi K, Nakagawa S, Kasuga S, Takane K, Furukawa Y Cancer Med. 2023; 12(12):13426-13437.

PMID: 37096864 PMC: 10315817. DOI: 10.1002/cam4.5970.

A streamlined tandem tip-based workflow for sensitive nanoscale phosphoproteomics.

Tsai C, Wang Y, Hsu C, Kitata R, Chu R, Velickovic M Commun Biol. 2023; 6(1):70.

PMID: 36653408 PMC: 9849344. DOI: 10.1038/s42003-022-04400-x.

PTMint database of experimentally verified PTM regulation on protein-protein interaction.

Hong X, Li N, Lv J, Zhang Y, Li J, Zhang J Bioinformatics. 2022; 39(1).

PMID: 36548389 PMC: 9848059. DOI: 10.1093/bioinformatics/btac823.

References

Tipping A, Baluch S, Barnes D, Veach D, Clarkson B, Bornmann W . Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia. 2004; 18(8):1352-6. DOI: 10.1038/sj.leu.2403416. View

Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K . BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet. 2001; 30(1):48-58. DOI: 10.1038/ng791. View

Reya T, Clevers H . Wnt signalling in stem cells and cancer. Nature. 2005; 434(7035):843-50. DOI: 10.1038/nature03319. View

Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R . A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature. 2005; 438(7069):873-7. PMC: 2100418. DOI: 10.1038/nature04185. View

Kikuchi A . Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci. 2003; 94(3):225-9. PMC: 11160305. DOI: 10.1111/j.1349-7006.2003.tb01424.x. View

Gunby R, Tartari C, Porchia F, Donella-Deana A, Scapozza L, Gambacorti-Passerini C . An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase. Haematologica. 2005; 90(7):988-90. View

Cole A, Frame S, Cohen P . Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem J. 2003; 377(Pt 1):249-55. PMC: 1223856. DOI: 10.1042/BJ20031259. View

Huntly B, Shigematsu H, Deguchi K, Lee B, Mizuno S, Duclos N . MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004; 6(6):587-96. DOI: 10.1016/j.ccr.2004.10.015. View

Deininger M, Buchdunger E, Druker B . The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2004; 105(7):2640-53. DOI: 10.1182/blood-2004-08-3097. View

10.

Goldman J, Melo J . Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med. 2003; 349(15):1451-64. DOI: 10.1056/NEJMra020777. View

11.

de Groot R, Raaijmakers J, Lammers J, Koenderman L . STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun. 2000; 3(5):299-305. DOI: 10.1006/mcbr.2000.0231. View

12.

Gottardi C, Gumbiner B . Role for ICAT in beta-catenin-dependent nuclear signaling and cadherin functions. Am J Physiol Cell Physiol. 2003; 286(4):C747-56. DOI: 10.1152/ajpcell.00433.2003. View

13.

Golas J, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J . SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003; 63(2):375-81. View

14.

Daley G . Chronic myeloid leukemia: proving ground for cancer stem cells. Cell. 2004; 119(3):314-6. DOI: 10.1016/j.cell.2004.10.015. View

15.

Davidson G, Wu W, Shen J, Bilic J, Fenger U, Stannek P . Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature. 2005; 438(7069):867-72. DOI: 10.1038/nature04170. View

16.

Wilson M, Schreiner S, Choi H, Kamens J, Smithgall T . Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene. 2002; 21(53):8075-88. DOI: 10.1038/sj.onc.1206008. View

17.

Henderson B, Fagotto F . The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep. 2002; 3(9):834-9. PMC: 1084234. DOI: 10.1093/embo-reports/kvf181. View

18.

Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D . MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res. 2005; 65(22):10413-22. DOI: 10.1158/0008-5472.CAN-05-2474. View

19.

Staal F, Clevers H . WNT signalling and haematopoiesis: a WNT-WNT situation. Nat Rev Immunol. 2005; 5(1):21-30. DOI: 10.1038/nri1529. View

20.

Coluccia A, Benati D, Dekhil H, De Filippo A, Lan C, Gambacorti-Passerini C . SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res. 2006; 66(4):2279-86. DOI: 10.1158/0008-5472.CAN-05-2057. View